Japanese Eisai demands to stop a generic turn eribulina from "Promomed"

The producer of an original oncological preparation Halaven (eribulin) the Japanese company demands Eisai through court to stop production and deliveries domestic generic Eribulin-Promomed from companies Group of companies "Promomed" and to cancel his registration. While at foreign pharmaceutical companies it is impossible to influence preparation realization. Courts froze claim Eisai before emergence of the decision on the parallel claim "Promomed" who in turn tries to challenge the patent of the Japanese competitor existing till 2024. Experts predict that Eisai will not manage to achieve success in vessels before the patent expiration...